Final results of a phase II multicenter trial of HF10, a replication-competent HSV-1 oncolytic virus, and ipilimumab combination treatment in patients with stage IIIB-IV unresectable or metastatic melanoma.

被引：41

作者：

Andtbacka, Robert Hans Ingemar

Ross, Merrick I.

Agarwala, Sanjiv S.

Taylor, Matthew H.

Vetto, John T.

Neves, Rogerio Izar

Daud, Adil

Khong, Hung T.

Ungerleider, Richard S.

Tanaka, Maki

Grossmann, Kenneth F.

机构：

[1] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[2] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[3] Temple Univ, St Lukes Canc Ctr, Bethlehem, PA USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[5] Penn State Hershey Canc Inst, Hershey, PA USA

[6] Univ Calif San Francisco, San Francisco, CA USA

[7] Theradex, Princeton, NJ USA

[8] Takara Bio Inc, Otsu, Shiga, Japan

来源：

关键词：

D O I：

10.1200/JCO.2017.35.15_suppl.9510

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

9510

引用

页数：5